Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Recursion Pharmaceuticals (NASDAQ: RXRX) Forms Powerful Partnership with NVIDIA (NASDAQ: NVDA)

A $50 Million Investment to Boost AI Capabilities in Drug Discovery

Recursion Pharmaceuticals (NASDAQ: RXRX), a trailblazer in TechBio that is revolutionizing the field of drug discovery, has received a $50 million investment from NVIDIA (NASDAQ: NVDA). The collaboration aims to expedite the development of Recursion’s AI foundation models for biology and chemistry, leveraging NVIDIA’s cloud services for broader distribution among biotechnology companies.

Unleashing the Power of AI in Biotechnology

“Recursion and NVIDIA: Pioneering Drug Discovery with AI” defines the venture as a fusion of two leading-edge companies, combining their strength to tackle the complex issue of drug discovery. Utilizing Recursion’s vast biological and chemical dataset, which surpasses 23 petabytes and contains 3 trillion searchable gene and compound relationships, the partnership will propel the training of foundation models on NVIDIA DGX™ Cloud. These models could then be licensed for commercial use on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.

Expanding AI Potential with NVIDIA’s Expertise

“NVIDIA’s Role in Recursion’s AI Evolution” underscores the tech giant’s crucial role in optimizing and scaling Recursion’s foundation models. NVIDIA will bring its comprehensive computing expertise and robust AI stack into play. BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery, introduced earlier this year, offers tools for the swift customization and deployment of domain-specific, state-of-the-art biomolecular models at scale via cloud APIs. Recursion plans to use this software to bolster its internal pipeline as well as to aid its current and upcoming partners.

Pioneering Work in Digital Biology and Chemistry

In “Revolutionizing Medicine with Generative AI”, NVIDIA’s founder and CEO Jensen Huang applauds Recursion’s pioneering efforts in digital biology and chemistry. He notes that generative AI is an innovative tool to unearth new medicines and treatments, and looks forward to working with Recursion’s world-class team to accelerate the development of the world’s largest biomolecular generative AI models. The collaboration aims to expedite drug discovery processes for biotech and pharmaceutical companies.

Recursion Pharmaceuticals’s Democratizing Efforts in Drug Discovery

Following its recent acquisition of Valence Discovery, Recursion strives to expedite the development of new technologies within the biopharma industry. “Recursion: Democratizing Access to Large-Scale Models” illustrates the company’s commitment to making such large-scale models more accessible, aiming for maximum impact in drug discovery. With this innovative approach, Recursion continues to break new ground in the biotech and pharmaceutical landscape.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Recursion Pharmaceuticals (NASDAQ: RXRX) Forms Powerful Partnership with NVIDIA (NASDAQ: NVDA) appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.